473730-88-0

Basic information

• Product Name: 3-METHYLPIPERIDIN-3-OL
• Synonyms: 3-METHYLPIPERIDIN-3-OL;3-Hydroxy-3-methylpiperidine;3-Hydroxy-3-methylpiperid...;3-methylpiperidin-3-ol hydrochloride;3-methylpiperidin-3-ol(SALTDATA: FREE);3-Methyl-3-Piperidinol;3-Piperidinol,3-methyl-
• CAS NO: 473730-88-0
• Molecular Formula: C₆H₁₃NO
• Molecular Weight: 115.18
• Mol File: 473730-88-0.mol

Chemical Properties

• Boiling Point: 190.977 °C at 760 mmHg
• Flash Point: 85.603 °C
• Appearance: /
• Density: 0.977 g/cm³
• Vapor Pressure: 0.142mmHg at 25°C
• Refractive Index: 1.465
• Storage Temp.: 2-8°C(protect from light)
• PKA: 14.97±0.20(Predicted)
• CAS DataBase Reference: 3-METHYLPIPERIDIN-3-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 3-METHYLPIPERIDIN-3-OL(473730-88-0)
• EPA Substance Registry System: 3-METHYLPIPERIDIN-3-OL(473730-88-0)

Safety Data

• RIDADR: UN2811
• Hazardous Substances Data: 473730-88-0(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
3-Methylpiperidin-3-ol is used as a building block in the synthesis of more complex organic compounds, leveraging its piperidine ring and functional groups for the creation of a variety of chemical products.
Used in Pharmaceutical Research:
3-Methylpiperidin-3-ol is used as a potential bioactive molecule in pharmaceutical research, where its structure may contribute to the development of new drugs, particularly in the context of its interactions with biological targets.

InChI:InChI=1/C6H13NO/c1-6(8)3-2-4-7-5-6/h7-8H,2-5H2,1H3

Upstream product

• 626-56-2 3-Methylpiperidine 
• 6560-72-1 1-benzyl-3-methyl-piperidin-3-ol 
• 98977-36-7 3-oxo-piperidine-1-carboxylic acid tert-butyl ester 
• 1104083-27-3 tert-butyl 3-hydroxy-3-methylpiperidine-1-carboxylate 

Downstream Products

• 19980-02-0 (3-hydroxy-3-methylpiperidin-1-yl)(phenyl)methanone 
• 1443118-58-8 (3-hydroxy-3-methylpiperidin-1-yl)(4-((4-methoxyphenyl)ethynyl)phenyl)methanone 
• 1200131-26-5 1-(4-bromobenzyl)-3-methylpiperidin-3-ol 

Relevant articles and documents

Remote C(sp3)-H Oxygenation of Protonated Aliphatic Amines with Potassium Persulfate

This letter describes the development of a method for selective remote C(sp3)-H oxygenation of protonated aliphatic amines using aqueous potassium persulfate. Protonation serves to deactivate the proximal C(sp3)-H bonds of the amine substrates and also renders the amines soluble in the aqueous medium. These reactions proceed under relatively mild conditions (within 2 h at 80 °C with amine as limiting reagent) and do not require a transition metal catalyst. This method is applicable to a variety of types of C(sp3)-H bonds, including 3°, 2°, and benzylic C-H sites in primary, secondary, and tertiary amine substrates.

Discovery of (R)-(2-fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl) (3-hydroxypiperidin-1-yl)methanone (ML337), an mGlu3 selective and CNS penetrant negative allosteric modulator (NAM)

A multidimensional, iterative parallel synthesis effort identified a series of highly selective mGlu3 NAMs with submicromolar potency and good CNS penetration. Of these, ML337 resulted (mGlu3 IC50 = 593 nM, mGlu2 IC50 >30 μM) with B:P ratios of 0.92 (mouse) to 0.3 (rat). DMPK profiling and shallow SAR led to the incorporation of deuterium atoms to address a metabolic soft spot, which subsequently lowered both in vitro and in vivo clearance by >50%.

2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME

The present invention provides 2-substituted-ethynylthiazole derivatives of formula (I): wherein R1, R2 and X are as defined herein, or a pharmaceutically acceptable salt thereof; and pharmaceutical compositions and methods of using same.

FUSED BENZENE DERIVATIVE AND USE

The present invention provides a compound represented by the general formula: [wherein Ring A represents an optionally substituted 5- to 8-membered ring, Ring B represents a further optionally substituted 4- to 10-membered ring, Ring C represents a further optionally substituted benzene ring, X1 represents carbon atom, X2 represents a carbon atom, an oxygen atom, etc., W represents a nitrogen atom, etc., Y11 represents a group represented by the formula CR2R3' (wherein R2 represents a hydrogen atom, a cyano group, a nitro group, etc., and R3' represents a hydrogen atom, a cyano group, a nitro group, etc., respectively), Y21 represents a group represented by the formula CR4R5' (wherein R4 represents a hydrogen atom, a cyano group, a nitro group, etc., and R5' represents a hydrogen atom, a cyano group, a nitro group, etc., respectively), etc., and R1 represents an electron-withdrawing group, respectively. The formula represents a single bond or a double bond] or a salt thereof, which is useful as an androgen receptor modulator.

QUINOLONE ANTIBACTERIAL AGENTS

Compounds of formula (I, II, III, IV, V, and VI) and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula (I) as well as pharmaceutically acceptable compositions comprising compounds of formula (I). Compounds of formula (I) as disclosed herein can be used in a variety of applications including use as antibacterial agents.

THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of Formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of Formula (IA).

ISOTHIAZOLE DIOXIDES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA): and the pharmaceutically acceptable salts and solvates thereof. D and E are different groups wherein one is N and the other is CR50. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.

THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.